{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:44:46Z","timestamp":1786977886369,"version":"build-2736575974"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Tuberculosis (TB) remains a significant global health concern, especially in Nepal, where the incidence of anti\u2010TB drug\u2010induced liver injury (DILI) is substantial. The main aim of this study is to investigate the incidence, clinical characteristics, outcomes, and contributing factors related to intensive phase anti\u2010TB DILI among TB patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective cross\u2010sectional study enrolled 78 TB patients. Patients received a weight\u2010based fixed\u2010dose Antitubercular therapy (ATT). Liver function tests (LFTs) were performed at baseline and periodically during treatment to monitor for anti\u2010TB DILI. Patients with DILI received immediate ATT discontinuation, supportive care, and reintroduction of ATT upon LFT normalization. Outcomes were tracked up to 60 days post\u2010DILI. Data were analyzed using SPSS v21. Statistical significance was set at\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean age of the patients was 49.87 years (SD\u2009=\u200918.61), and 57.7% were male. Anti\u2010TB DILI was observed in 15.4% of patients during the intensive treatment phase, with moderate severity in 50% of these cases. Half of the patients with DILI presented with nausea, vomiting, and anorexia. Notably, 91.7% of DILI patients showed improvement upon treatment discontinuation. The recurrence rate of anti\u2010TB DILI after ATT re\u2010initiation was 8.3%. Anti\u2010TB DILI developed at a median of 11 days (range: 7\u201360 days) after ATT initiation, with liver enzyme normalization after discontinuation of ATT averaging 10.9\u2009\u00b1\u20096.45 days. The mortality rate among DILI patients was 8.3% (1 out of 12 patients). Hepatotoxic drugs, low BMI, and low serum albumin were identified as independent predictors of anti\u2010TB DILI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti\u2010TB DILI occurred in a significant proportion of TB patients, with moderate severity being most common. Early detection and management, including treatment discontinuation, led to high recovery rates, though mortality remained notable. Low BMI, low serum albumin, and hepatotoxic drugs were key independent risk factors, emphasizing the need for careful monitoring and tailored management during ATT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.70686","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:20:36Z","timestamp":1745230836000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence, Clinical Features, Associated Factors and Outcomes of Intensive Phase Antituberculosis Drug Induced Liver Injury Among Patients With Tuberculosis at a Tertiary Care Hospital in Nepal: A Descriptive Cross\u2010Sectional Study"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-3029","authenticated-orcid":false,"given":"Ravi Ranjan","family":"Pradhan","sequence":"first","affiliation":[{"name":"Dhaulagiri Hospital Baglung Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-5783","authenticated-orcid":false,"given":"Ajay Kumar","family":"Yadav","sequence":"additional","affiliation":[{"name":"National Academy of Health Sciences Kathmandu Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70030-6"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2006.01.007"},{"issue":"7899","key":"e_1_2_14_4_1","first-page":"119","article-title":"Short\u2010Course Chemotherapy in Pulmonary Tuberculosis","volume":"1","author":"British T.","year":"1975","journal-title":"Lancet"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09102026"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021836"},{"issue":"1","key":"e_1_2_14_7_1","first-page":"32","article-title":"Prevalence and Management out Comes of Anti TB Drugs Induced Hepatotoxicity, St. Peter TB Specialized Hospital","volume":"4","author":"Mekonnen T.","year":"2002","journal-title":"Journal of Ethiopian Medical Practise"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(86)90003-6"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0102-311X2012000400009"},{"issue":"6","key":"e_1_2_14_10_1","first-page":"1039","article-title":"Isoniazid Preventive Therapy: Retrospect and Prospect","volume":"121","author":"Dash L. A.","year":"1980","journal-title":"American Review of Respiratory Disease"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2012.07279.x"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2003.008664"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2330-z"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1033-7"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05207.x"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777X.170499"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(90)90124-A"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21563"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2020\/46053.14132"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7401541"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-008-9085-y"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241346"},{"issue":"3","key":"e_1_2_14_24_1","first-page":"384","article-title":"Common Risk Factors for the Development of Anti Tuberculosis Treatment Induced Hepatotoxicity","volume":"26","author":"Abbasi M. A.","year":"2014","journal-title":"Journal of Ayub Medical College, Abbottabad"},{"issue":"9","key":"e_1_2_14_25_1","first-page":"994","article-title":"Drug\u2010Metabolising Enzyme Polymorphisms and Predisposition to Anti\u2010Tuberculosis Drug\u2010Induced Liver Injury: A Meta\u2010Analysis","volume":"12","author":"Sun F.","year":"2008","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.6.9711039"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0962-8479(94)90104-X"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2004.10.009"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(77)90022-8"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0962-8479(96)90073-8"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024935"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064622"},{"key":"e_1_2_14_33_1","unstructured":"H.Khalili K. S.Dashti M.Rasoulinezhad L.Rezaei andM.Etminani \u201cAnti\u2010Tuberculosis Drugs Related Hepatotoxicity; Incidence Risk Factors Pattern of Changes in Liver Enzymes and Outcome \u201d 2009 https:\/\/www.sid.ir\/EN\/VEWSSID\/J_pdf\/85820090304.pdf."},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.01.014"},{"issue":"8","key":"e_1_2_14_35_1","first-page":"699","article-title":"Hepatotoxicity of Tuberculosis Chemotherapy Under General Programme Conditions in Singapore","volume":"6","author":"Teleman M. D.","year":"2002","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.4103\/2249-4863.154661"},{"issue":"2","key":"e_1_2_14_37_1","first-page":"134","article-title":"Drug\u2010Induced Hepatitis (Abundance and Outcome During Course of Tuberculosis Treatment): Seven\u2010Year Study on 324 Patients With Positive Sputum in Iran","volume":"16","author":"GhasemiBarghi R.","year":"2011","journal-title":"Govaresh"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0377-1237(06)80155-3"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2108091"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.4103\/2249-4863.154661"},{"issue":"1","key":"e_1_2_14_41_1","first-page":"72","article-title":"Risk Factors for Anti Tuberculous Drugs Induced Hepatitis: A Prospective Survey From a Chest Clinic in a General Hospital","volume":"59","author":"Fauzi A. R.","year":"2004","journal-title":"Medical Journal of Malaysia"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064622"},{"issue":"9","key":"e_1_2_14_43_1","first-page":"688","article-title":"Prevalence and Risk Factors of Anti\u2010Tuberculosis Drug\u2010Induced Hepatitis in Malaysia","volume":"49","author":"Marzuki O. A.","year":"2008","journal-title":"Singapore Medical Journal"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.70686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T22:24:49Z","timestamp":1746397489000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.70686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/hsr2.70686"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.70686","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70686"}}